A comparison of the extended-release and standard-release formulations of tacrolimus in de novo kidney transplant recipients: A 12-month outcome study

Clinical Kidney Journal

Volumn 6, Issue 1, 2013, Pages 45-49

  Fanous, Helen ^a,b   Zheng, Rebecca ^a,b   Campbell, Carolyn ^a   Huang, Michael ^a   Nash, Michelle M ^a   Rapi, Lindita ^a   Zaltzman, Jeffrey S ^a   Prasad, G V Ramesh ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

complications; immunosuppression; outcome

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BK VIRUS INFECTION; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 84873378729     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfs169     Document Type: Article

References (14)

1. Kramer BK, Charpentier B, Backman L et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de-novo renal transplantation: a randomized phase III study. Am J Transplant 2010; 10: 2632-2643
2. Prasad GV, Nash MM, McFarlane PA et al. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors. Nephron Clin Pract 2004; 97: 35-40
3. Hardinger KL, Park JM, Schnitzler MA et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant 2004; 4: 621-625
4. Guirado L, Cantarell C, Franco A et al. for the GREAT Study Group. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011; 11: 1965-1971
5. Lauzurica R, Morales JM, van Hooff J. Renal function and safety in stable kidney transplant recipients converted from immediate-release to extended-release tacrolimus. Transplant Int 2012; 25: 48-55
6. Kolonko A, Chudek J, Wiecek A. Improved kidney graft function after conversion from twice daily tacrolimus to a once daily extended-release formulation. Transplant Proc 2011; 43: 2950-2953
7. Alloway R, Steinberg S, Khalil K et al. Two years postconversion from a Prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007; 83: 1648-1651
8. Silva HT, Yang HC, Abouljoud M et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/ MMF in de-novo kidney transplant recipients. Am J Transplant 2007; 7: 595-608
9. Undre NA, van Hooff J, Christiaans M et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296-298
10. de Jonge H, Kuypers DR, Verbeke K et al. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523-529
11. Hougardy JM, Broeders N, Kianda M et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566-569
12. Harrison JJ, Schiff JR, Coursol CJ et al. Generic immunosuppression in solid organ transplantation : a Canadian perspective. Transplantation 2012; 93: 657-665
13. Hougardy J-M, de Jonge H, Kuypers D et al. The once-daily formulation of tacrolimus: A step forward in kidney transplantation? Transplantation 2012; 93: 241-243
14. Wang P, Mao Y, Razo J et al. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Pharmacogenomics 2010; 11: 1389-1402